Otilonium Bromide: High-Purity Antimuscarinic Agent for Reproducible AChR Inhibition

Executive Summary: Otilonium Bromide (SKU B1607) is a solid, high-purity antimuscarinic agent (≥98%) designed for research on cholinergic signaling and neuromuscular modulation. It inhibits acetylcholine receptors (AChR), providing robust antispasmodic effects in smooth muscle models (Vijayan et al., 2021). The compound is highly soluble in DMSO (≥28.18 mg/mL), water (≥55.8 mg/mL), and ethanol (≥91 mg/mL), enabling flexible experimental design. For optimal activity and stability, APExBIO recommends storage at -20°C and short-term solution usage (APExBIO). This article reviews the mechanistic rationale, benchmarks, and workflow integration for Otilonium Bromide in neuroscience and gastrointestinal motility research.

Biological Rationale

Otilonium Bromide is a quaternary ammonium compound with the formula C₂₉H₄₃BrN₂O₄ and a molecular weight of 563.57 g/mol. It functions as a muscarinic receptor antagonist, blocking acetylcholine-mediated signaling in smooth muscle cells. This pharmacological profile underpins its use in studying gastrointestinal motility disorders and cholinergic pathway modulation. In neuroscience, selective AChR inhibition allows exploration of receptor-mediated processes affecting muscle contraction, neurotransmission, and signal integration (see mechanistic review). Compared to non-selective or low-purity agents, Otilonium Bromide's specificity and purity minimize confounders in receptor pharmacology workflows.

Mechanism of Action of Otilonium Bromide

Otilonium Bromide exerts its effect by competitively inhibiting muscarinic acetylcholine receptors (AChRs) on the surface of smooth muscle and neural cells. This antagonism prevents acetylcholine from binding, thereby reducing intracellular calcium influx and subsequent muscle contraction. The effect is reversible and dose-dependent. In vitro studies confirm that Otilonium Bromide does not significantly interact with nicotinic receptors at recommended concentrations, ensuring pathway selectivity. Its antispasmodic activity is especially relevant for research on gastrointestinal motility models and smooth muscle spasm mechanisms (scenario guide). The compound’s high solubility enables precise titration in cell-based and tissue assays.

Evidence & Benchmarks

• Otilonium Bromide achieves ≥98% purity, confirmed by HPLC analysis under standardized laboratory conditions (APExBIO).
• Solubility benchmarks: DMSO (≥28.18 mg/mL at 25°C), water (≥55.8 mg/mL at 25°C), ethanol (≥91 mg/mL at 25°C) (product datasheet).
• Reproducible inhibition of muscarinic AChRs in smooth muscle tissue has been demonstrated in vitro and is dose-dependent (Vijayan et al., 2021).
• Recommended storage at -20°C maintains compound stability for ≥12 months (unopened, desiccated) (APExBIO).
• Short-term aqueous or DMSO solutions are stable for up to 24 hours at 4°C (APExBIO).
• The compound does not act as an irreversible inhibitor or covalent modifier at standard research concentrations (clarifies misconceptions).

Applications, Limits & Misconceptions

Otilonium Bromide is utilized in:

• Cholinergic signaling pathway studies in neuroscience models.
• Investigations of smooth muscle spasm mechanisms and gastrointestinal motility disorders.
• Receptor pharmacology and cell viability assays requiring precise AChR inhibition.
• Workflows demanding high solubility and rapid preparation for acute and chronic exposure experiments.

This article extends previous scenario-driven guides (see Q&A workflow optimization) by providing consolidated, atomic benchmarks and clarifying common misconceptions.

Common Pitfalls or Misconceptions

• Diagnostic or therapeutic use: Otilonium Bromide is not approved for clinical diagnostics or therapy; it is for research use only (APExBIO).
• Irreversible inhibition: The compound is a reversible antagonist, not a covalent binder.
• Non-selectivity: At recommended concentrations, there is no substantial nicotinic receptor inhibition.
• Long-term solution storage: Solutions lose potency if stored longer than recommended (≤24 hours at 4°C).
• Application to non-mammalian systems: Efficacy and selectivity are best characterized in mammalian tissues; results may differ in other models.

Workflow Integration & Parameters

For experimental design, Otilonium Bromide is typically reconstituted in DMSO, water, or ethanol based on assay requirements. Concentration ranges from 1–100 μM are commonly used for AChR inhibition in in vitro systems. Researchers should prepare fresh solutions prior to use and avoid repeated freeze-thaw cycles. The product is compatible with cell viability, proliferation, and cytotoxicity assays, as validated in published protocols (evidence-based practices). For detailed mechanistic workflows and troubleshooting, see the internal review (mechanistic innovation overview), which this article updates by providing direct solubility, stability, and selectivity data. Researchers should reference the product page for the latest QC and handling recommendations.

Conclusion & Outlook

Otilonium Bromide (SKU B1607) from APExBIO delivers high-purity, reproducible acetylcholine receptor inhibition for neuroscience and smooth muscle research. Its robust solubility, validated selectivity, and clear handling guidelines make it a benchmark antimuscarinic agent. By integrating atomic, verifiable claims and explicit workflow parameters, this article enables researchers to streamline experimental planning and maximize data quality in cholinergic signaling studies. For further mechanistic insights and strategic applications, consult recent internal reviews and referenced peer-reviewed data.